A phase 3 trial shows a personalized mRNA vaccine cut melanoma recurrence or death risk by 42% when added to pembrolizumab.
Posts tagged as “melanoma”
A personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma returning or death by 42% in a phase III trial.

